Registered number: 01723353
Charity number: 326374
THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
UNAUDITED
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
CONTENTS
Page
Reference and administrative details of the Society, its Council members and
advisers
Council members. report
Independent examiner's report
Statement of financial activities
Balance sheet
10-11
Notes to the financial statements
12-21

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE SOCIETY, ITS COUNCIL MEMBERS AND
ADVISERS
FOR THE YEAR ENDED 31 MARCH 2024
Council members
Dr D Roberts, President
Dr G D Poole
Mrs C E George
Dr I Sullivan
Mr R C Haggas, Treasurer
Miss J Staves
Mrs R Braund
Dr N Osaro
Mr D Gaskin (appointed 30 January 2024)
Company registered
number
01723353
Charity registered
number
326374
Registered office
CIO Armstrong Watson 1st Floor
One Strawberry Lane
Newcaslle Upon Tyne
NE14BX
BBTS Executive
Manager
David Noble
Accountants
Armstrong Watson LLP
Chartered Accountants
First Floor
One Strawbery Lane
Newcaslle Upon Tyne
NE14BX
Solicitors
Hay & Kilner LLP
The Lumen
St James, Boulevard
Newcastle Helix
Newcaslle upon Tyne
NE4 5BZ

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT
FOR THE YEAR ENDED 31 MARCH 2024
The Council members present their annual report together with the financial statements of the The British Blood
Transfusion Society for the year 1 April 2023 to 31 March 2024. The report serves the purposes of both a
Council members, report and a directors. report under company law.
The Council members confim that the report and financial statements of the charitable company comply with
the current statutory requirements, the requirements of the charitable company's goveming document and the
provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts
in accordan￿ with the Financial Reporting Standard applicable in the UK and Republic of Ireland {FRS102)
(effective 1 January 2019).
Structure, governance and management
a. Governing document
The British Blood Transfusion Society was established in May 1983 as a company limited by guarantee
governed by its Memorandum and Artides of Association (revised September 2011 }. It is registered as a charity
with the Charity Commission. Every member undertakes to contribute such an amount not exceeding £1, as
may be required in the event of the Society being wound up while he is a member or within one year after they
cease to be a member.
b. Appointment of Council members
The Council members consist of officers. elected members and Past President or President Elect. Officers
consist of the President of the Society who holds Offi￿ for years and the Secretary and Treasurer who hold
office for three years. The President can remain as a Council member for a further year after retirement from
the office of President The Secretary and Treasurer are eligible for reappointment by Council, but neither can
serve more than six consecutive years in office.
The elected Council members shall be those members of the Council who are not officers and shall each hold
office for a period of three years,. so far as possible they shall be made up of a mix of professional categories
and be representative of the current membership; the period of office may be extended from time to time by the
President for a year with a maximum of three extensions providing a maximum term of six years.
The Council members of the charitable company (exduding c(FOPted members) are its directors for the
purposes of company law and trustees for the purposes of charity law. The elected Council members hold offi
for a period of three years.
Calls for nominations for officers and elected members of Council are made in the BBTS Bloodlines Newsletter
and also on the Society's website. Nominees must be UK members and must have been a member of the
Society for a minimum of years. Nominations must be proposed and seconded by Society members.
Details of the nominees are then published on the ballot papers.
c. Induction and training of Council members
All new Council members are given an induction pack containing infomation, links and papemork about the
roles and responsibilities of trustees published by the Charity Commission. They also re￿1ve past Council
meeting papers and dates of forthcoming Council meetings.
At the first meeting of the new Council, new members are intrOdU￿d to individual Council members and
specific areas of responsibility for new members are discussed and agreed. The Society's office then provides
all the necessary background information and paperwork for new Council members, individual areas of
responsibility.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
Structure, governance and management (continued)
d. Organisation
The Society is managed by the Council members, who are responsible for the strategic direction and overview
of the work of the Society. The Council members must number at least eight and not more than fourteen, all of
whom must be members of the Society. Three Council members (induding at least one officer) are needed for
a quorum.
There are committees and sub-committees of Council members that may CCpOPt members who are not
members of the Council or Society. C(Fopted members may not ex￿ed thre&quarters of the total number of
such committees. These committees include the Executive Working Committee, the Scientific Meetings
Administration Committee, the Communications Committee and the Professional Affairs & Education
Committee.
The day to day operations of the charity are managed by the BBTS Executive Manager and a small team of
staff from an Offi￿ based in Manchester.
e. BBTS Enterprises Limited
The charity's wholly-owned subsidiary was incorporated in May 2003 and carries out trading activities for the
charity. The subsidiary gift aids profits to the charity, subject to the retention of reseNes for its own working
capital requirements.
f. Risk management
The members of the Council are responsible for overseeing the risks fa￿d by the Society. Within this process,
detailed consideration of risks is delegated to the Executive Manager. Risks are identified, assessed and
controls established throughout the year. Risks are held in a risk register. Council conducts ongoing reviews of
the major risks to which the Society is exposed.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
Objectives. activities and perfomiance
a. Objectives and activities
The main aim of the Society is to advan￿ for the public benefit, the study of blood transfusion including
immunohaematology and to promote research and development into all aspects of blood transfusion practice.
The objectives of the Society continue to be to:
Provide education and training, induding professional development
Provide a forum for discussion and communication and facilitate the exchange of ideas be￿een all
groups through scientific meetings, special interest groups {SIGs) and the website
Foster links with relevant national societies and organisations and ensure Society representation as
appropriate
Encourage research and development and disseminate information on new developments
Contribute to the production of professional guidelines and promote best practice in all aspects of
transfusion medicine
Ensure recognition as the professional body for transfusion medicine by the government, health services
and the public
Contribute to the advancement of knowledge and ServI￿S in developing countries
The Council sets itself annual objectives, in furtheran￿ of the above main objectives of the Society. Each
objective has a perf0mlan￿ measure and responsibility is allocated to a Council member or Council sul>
committee. Performan￿ against the annual objectives is reviewed at Council meetings throughout the year
and a progress report published in the Annual Review for members to view.
The Council confirm that they have been given the general guidance produced by the Charity Commission on
public benefit including the guidance 'public benefit running a charity (PB2)'. The Council are confident that
public benefit is achieved through the study of blood transfusion and development.
b. Achievements and performance
The Society's charitable activities focus on the study of ￿00d transfusion and are undertaken to further its
charitsble purposes for the public benefit as described in the following paragraphs:
The Society delivered its annual conference event in October 2023. The conference was held at the
Harrogate HIC. The Society met its AGM obligations to members on time.
The Society continued to protect its finances during the year and worked hard for members to ensure it
can continue and expand on its works and activities in the years ahead.
The education programmes continue to provide valuable education and training opportunities and set out
transfusion best practi￿. 160 people took an examination with an overall 850/0 pass rate and 76 text books were
separately purchased. Our VLE software was upgraded for the third consecutive year. The Moodle exam
platform software, induding online marking. perfomed well.
The CPD scheme provides a specific framework for transfusion professionals. This year the Society had
522 members who were both registered and active on the scheme. CPD News continues to provide members
relevant opportunities to learn and reflecL The Society continues to improve its online CPD tool for members to
populate and submit returns electronically.
Through engagement with all members at every step the Society has continued to work dosely with its
Equality, Diversity and Indusion Committee establishing further updated Terms of Reference.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
Objectives. activities and perfomiance (continued)
(continued)
Successfully delivering six editions of the Society's Transfusion Medicine joumal and four editions of its
membership magazine Bloodlines.
The Society has continued its representations as a professional body working towards the delivery of safe
and effective transfusion practice.
During the year, Council achieved many of its major objectives induding the improvement of our online course
delivery and online exams, maintaining a strong Transfusion Medicine impact factor and gaining a respectable
financial return from this journal.
The Society continues to work hard to rewrite and add to its CTP course content and now has new Course
Leads. We are planning to relaunch the course in 2025. We provided one educational webinar. The Transfusion
Practitioners group has appointed a new Chair and Secretary as has the Components Special Interest Group.
We continued to mitigate financial risk to the Society during this period whilst remaining almost entirely
financially independent.
Membership of the Society has changed during the year as follows..
Number of members on 1 April 2023
Number of new members
Number of members who left
Number of members on 31 March 2024
1,490
191
(175)
1,506
Financial review
a. Results
The principal funding sources of the Society are from training income and membership subscriptions. Income
from these sources is shown in note 5 to the financial statements.
The net movement in funds for the year was a deficit of £5,459 (2023.. surplus £14,539), as shown in the
statement of financial activities. There was a gift aid donation of £4,390 (2023.. £nil) from the subsidiary this
year, so the operational deficit was £9,849 (2023.. surplus of £14,539). The group deficit for the year was
£11,085 (2023: surplus £19,085).
b. Reserves policy
Council has established a policy whereby the unrestricted funds not committed, designated or invested in
tangible fixed assets (the free reserves) held by the group should equate to at least £400,000. The reserves are
needed to meet the ongoing working capital requirements of the group, to bridge any funding gaps during the
development of new activities and to enable the group to continue its current activities in the event of a
significant drop in income.
The free reserves of the charity as at 31 March 2024 were £398,652 {2023. £403,196) and those of the trading
subsidiary add a further £88,980 (2023. £94,606), a total of £487,632 (2023. £497,802).

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
c. Investment powers and policy
Under the Memorandum and Artides of Association, the Society has the power to make investments as the
Council members see fiL
Having regard to the Society's liquidity requirements and reserves policy, Council have, in recent years,
operated a policyof keeping available funds in interest-bearing deposit accounts.
d. Going concem
After making appropriate enquiries, the Council members have a reasonable expectation that the Society has
adequate resources to continue in operational existen￿ for the foreseeable future. For this reason, they
continue to adopt the going concem basis in preparing the financial statements. Further details regarding the
adoption of the going concern basis can be found in the accounting policies.
Plans for future periods
The Council has set itself a number of annual objectives for 2024125, in furtherance of the main objectives of
the Society. These objectives indude the following..
building on the strategies for membership expansion"
a written update of its Transfusion Science Practice coursebook"
relaunch of its Clinical Transfusion Practi￿ course"
to deliver more online webinars-
continually enhance our online exams to improve delivery and marking.,
bring our SIGS and their goals closer to the day to day work of Council.,
continue to re-enforce our relationships with other professional bodies.,
launch a new membership grade for non-degree transfusion workers,.
introduce a new Earfy Career Professionals committee;
create and launch an upgraded website and a BBTS mobile app;
review the feasibility of awarding Chartered Scientist status-
continue to ensure its finances are adequate following a withdrawal of funding-
review alterative Conferen￿ venues to protect our finances and reserves

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
COUNCIL MEMBERS. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
Statement of Council members. responsibilities
The Council members (who are also the directors of the Society for the purposes of company lawl are
responsible for preparing the Council members. report induding the Strategic report and the financial
statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom
Generally AC￿pted Accounting Practice).
Company law requires the Council members to prepare financial statements for each financial year. Under
company law, the Council members must not approve the financial statements unless they are satisfied that
they give a true and fair view of the state of affairs of the Society and of its incoming resources and application
of resources, including its income and expenditure, for that period. In prepanng these financial statements, the
Council members are required to=
select suitable accounting policies and then apply them consistenuy.,
observe the methods and principles of the Charities SORP (FRS 102).,
make judgments and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any
material departures disdosed and explained in the financial statements.,
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
Society will continue in business.
The Council members are responsible for keeping adequate accounting records that are sufficient to show and
explain the Society's transactions and disclose with reasonable accuracy at any time the financial position of the
Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are
also responsible for safeguarding the assets of the Society and hence for taking reasonable steps for the
prevention and detection of fraud and other irregularities.
Approved by order of the members of the board of Council members and signed on their behalf by..
Dr D Roberts
Date: 12 September 2024

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2024
Independent examiner's report to the Council members of The British Blood Transfusion
Society {'the Society.)
I report to the charity Council members on my examination of the accounts of the Society for the year ended 31
March 2024.
Responsibilities and basis of report
As the Council members of the Society (and rts directors for the purposes of company law) you are responsible
for the preparation of the accounts in accordan￿ with the requirements of the Companies Act 2006 ('the 2006
Act,).
Having satisfied myself that the accounts of the Society are not required to be audited under Part 16 of the 2006
Act and are eligible for independent examination, I report in respect of my examination of the Society's accounts
carried out under section 145 of the Charities Act 2011 ('the 2011 Act,). In carrying out my examination I have
followed the Directions given by the Charity Commission under section 145{5)(b) of the 2011 Act.
Independent examiner's statement
I have completed my examination. I confim that no matters have come to my attention in connection with the
examination giving me cause to believe:
accounting records were not kept in respect of the Society as required by section 386 of the 2006 Act,. or
the accounts do not accord with those records,. or
the accounts do not comply wth the accounting requirements of section 396 of the 2006 Act other than
any requirement that the accounts give a 'true and fai¢ view which is not a matter considered as part of
an independent examination- or
the accounts have not been prepared in accordance with the methods and principles of the Statement of
Recommended Practice for accounting and reporting by charities lapplicable to charities preparing their
accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of
Ireland (FRS 10211.
I have no concerns and have come across no other matters in connection with the examination to which
attention should be drawn in this report in order to enable a proper understanding of the accounts to be
reached.
This report is made solely to the Society's Council members, as a body, in accordance with Part 4 of the
Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the
Society's Council members those matters l am required to state to them in an Independent examine¢s report
and for no other purpose. To the fullest extent permitted by law, I do not ac￿pt or assume responsibility to
anyone other than the Society and the Society's Council members as a body, for my work or for this report
Signed..
Dated: 8 October 2024
D R Gold BA FCA
Independent Examiner
Armstrong Watson LLP
One Strawberry Lane
Newcastle upon Tyne

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2024
Unrestricted
funds
2024
Restricted
funds
2024
Total
funds
2024
Total
funds
2023
Note
Income from:
Donations
4.568
13,337
257.776
24,000
28,568
13,337
257,776
38,000
4,Tt6
262,240
Investments
Charitable activities
Total income
275.681
24,000
299,681
304, 956
Expenditure on:
Charitable activities
281.140
24,000
305,140
290,417
Total expenditure
281.140
24,000
305,140
290,417
Net (expenditure) income and
movement in funds
{5,459
(5,459)
14,539
Reconciliation of funds:
Total funds brought fO￿ard
Net movement in funds
450,122
{5.459)
450,122
(5,459)
435, 583
14,539
Total funds carried forward
444.663
444,663
450, 122
The Statement of financial activities indudes all gains and losses recognised in the year.
The notes on pages 12 to 21 fomi part of these financial statements.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
REGISTERED NUMBER: 01723353
BALANCE SHEET
AS AT 31 MARCH 2024
2024
2023
Note
Fixed assets
Intangible assets
Tangible assets
Investments
10
44,956
1,054
44,956
1,969
11
12
46,011
46,926
Current assets
Debtors
13
137.115
391,329
100,972
478,541
Cash at bank and in hand
528.444
579,513
Creditors.. amounts falling due within one
year
14
(123.460)
(169, 985)
Net current assets
404,984
409,528
Total assets less current liabilities
450,995
456,454
Capital grant
(6,332)
(6, 332)
Net assets
444,663
450, 122
Total net assets
444,663
450, 122

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
REGISTERED NUMBER: 01723353
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2024
2024
2023
Note
Charity funds
Restricted funds
Unrestricted funds
15
15
444,663
450, 122
Total funds
444,663
450, 122
The Society was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordan￿ with
section 476 of Companies Act 2006.
The Council members acknowledge their responsibilities for complying with the requirements of the Act with
respect to accounting records and preparation of financial statements.
The financial statements have been prepared in accordan￿ with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by the Council members and signed on their
behalf by.
Dr D Roberts
Mr R C Haggas
Date: 12 September 2024
The notes on pages 12 to 21 form part of these financial statements.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
General information
The Society is a company limited by guarantee and has no share capital. The liability of each member in
the event of winding up is limited to £1.
Accounting policies
2.1 Basis of preparation of financial statements
The financial statements have been prepared in accordan￿ with the Charities SORP (FRS 102) -
Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard
applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
The financial statements are prepared in sterling which is the functional and presentation currency of
the charity.
The British Blood Transfusion Society meets the definition of a public benefit entity under FRS 102.
Assets and liabilities are initially recognised at historical cost or transaction value unless othemise
stated in the relevant accounting policy.
2.2 Income
All income is induded in the statement of financial activities when the charity is entitled to the
income and the amount can be quantified with reasonable accuracy. The following specific
policies are applied to path'cular categories of income..
Donations are re￿iVed by way of grants and donations and are induded in full in the Statement of
financial activities on a re￿1vable basis. The balan￿ of income received for specific purposes but
not expended during the period is shown in the relevant funds on the Balance sheeL Where income
is received in advance of entitlement of receipt, its recognition is deferred and induded in creditors
as deferred income. Where entitlement occurs before income is received, the income is accrued.
Income from charitable activities indudes income from membership subscriptions and training and is
recognised in the period in which the Society is entitled to re￿ipt. Deferred income represents
amounts re￿iVed for future periods and is released to the statement of financial activities for the
period for which it has been released.
2.3 Expenditure
Expenditure is recognised once there is a legal or constructive obligation to transfer economic
benefit to a third party, it is probable that a transfer of economic benefits will be required in
setuement and the amount of the obligation can be measured reliably.
Expenditure is dassified by activity. The costs of each activity are made up of the total of direct costs
and shared costs, induding support costs involved in undertaking each activity.
Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which
contribute to more than one activity and support costs which are not attributable to a single activity
are apportioned between those activities on a basis consistent with the use of resources.
Expenditure on charitable activities is incurred on directly undertaking the activities which further the
Society's objectives, as well as any associated support costs.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Accounting policies (continued)
2.3 Expenditure (continued)
All expenditure is indusive of irrecoverable VAT.
2A Interest receivable
Interest on funds held on deposit is induded when receivable and the amount can be measured
reliably by the Society., this is normally upon notification of the interest paid or payable by the
institution with whom the funds are deposited.
2.5 Intangible assets and amortisation
Intangible assets are initially recognised at cost After recognition, under the cost model, intangible
assets are measured at cost less any accumulated amortisation and any accumulated impairment
losses.
Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on
a straight-line basis over its expected useful life.
The estimated useful lives are as follows=
Website costs
5 years
2.6 Tangible fixed assets and depreciation
Tangible fixed assets are induded in the financial statements at their historical cost.
Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value
over their estimated useful lives.
Depreciation is provided on the following basis=
Fixtures and fittings
Computer equipment
200/0 On straight line basis
25 % On straight line basis
2.7 Investments
The investment in the subsidiary undertaking is induded in the financial statements at cosL The
financial statements for the Society indude only the indivdual parent charity and are not consolidated
to include the trading subsidiary. The parent charity is not required to prepare consolidated financial
statements under section 399 of the Companies Act 2006 and is excepted by section 139(2) of the
Charities Act 2011 from the requirement to prepare group accounts.
2.8 Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered.
Prepayments are valued at the amount prepaid net of any trade discounts due.
2.9 Cash at bank and in hand
Cash at bank indudes a current account and an instant access COIF Charities Deposit Fund
account

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Accounting policies (continued)
2.10 Liabilities
Liabilities and provisions are recognised when there is an obligation at the Balan￿ sheet date as a
result of a past event, it is probable that a transfer of economic benefit will be required in settlement,
and the amount of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the Society anticipates it will pay to settle the debt or the
amount it has re￿iVed as advanced payments for the goods or services it must provide.
2.11 Financial instruments
The Society only has financial assets and financial liabilities of a kind that qualify as basic financial
instruments. Basic financial instruments are initially recognised at transaction value and
subsequently measured at their settlement value.
2.12 Fund structure
General funds are unrestricted funds which are available for use at the discretion of the Council
members in furtherance of the general objectives of the Society and which have not been
designated for other purposes. The general fund is credited with subscriptions re￿iVed from
members and income from training courses and associated income. It is charged with the charitable
expenditure and govemance costs of the Society.
Designated funds comprise unrestricted funds that have been set aside by the Council members for
particular purposes. The aim and use of any designated fund is set out in the notes to the financial
statements.
Grants obtained for specific purposes are recognised in the financial statements as restricted funds.
Investment income, gains and losses are allocated to the appropriate fund.
2.13 Judgements and key sources of estimation uncertainty
In applying the Society's accounting policies, the Counal members are required to make
judgements, estimates and assumptions in determining the carrying amounts of assets and
liabilities. The Council members. judgements, estimates and assumptions are based on the best
and most reliable evidence available at the time when the decisions are made, and are based on
historical experien￿ and other factors that are considered to be applicable.
Due to the inherent subjectivity involved in making such judgements, estimates and assumptions,
the actual results and outcomes may differ. The estimates and underlying assumptions are reviewed
on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the
estimate is revised, if the revision affects only that period, or in the period of the revision and future
periods, if the revision affects both current and future periods

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Income from donations
Unrestricted Restricted
funds
funds
2024
2024
Total
funds
2024
Donations
4,568
4,568
24,000
Grants
24,000
4,568
24,000
28,568
Restricted
funds
2023
Total
funds
2023
Grants
38,000
38, 000
Investment income
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Bank interest
13,337
13,337
4,716
Charitable activities
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Membership subscriptions
Training
116,532
141,244
116,532
141.244
115,109
147,131
257,776
257,776
262, 240

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Independent examiner's remuneration
2024
2023
Fees payable to the Society's independent examiner for the independent
examination of the Society's annual accounts
Fees payable to the Society's independent examiner in respect of..
All other servi￿$ not induded above
1.228
1,170
8,833
7, 744
Total resources expended
Charitable
Governance
Total
Total
activities
costs
2024
2023
Direct costs
Meetings and conferences
Publicity and publications
Bursaries and awards
1,115
6.254
97
7,355
932
7.355
932
Educational programme
Modernising Scientific Careers
83,392
23,562
83,392
23,562
81,624
22,498
Allocated support costs
Staff costs
110,690
38,388
641
14,274 124,964 110,606
16,182
54,570
58,179
275
916
1,130
4,326
8.652
8.287
239
797
627
35296 305140 290417
OfFice costs
Depreciation
Accountancy fees
Legal and other professional fees
4,326
558
269 844
Stsff costs and numbers
2024
2023
Wages and salaries
National insurance costs
158,991
10.724
139.638
9,017
Pension costs
178 512
154 787
Average number of employees in the year
(all management and administrative)

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Council members. remuneration and expenses
During the year, no Council members re￿iVed any remuneration or other benefits (2023 - £NIL).
During the year ended 31 March 2024, expenses totalling £761 were reimbursed or paid directly to 4
Council members (2023 - £164 to 1 Council member).
10. Intangible assets
Website
Cost
At 1 April 2023
44,956
At 31 March 2024
44,956
Net book value
At 31 March 2024
44,956
At 31 March 2023
44, 956

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
11. Tangible fixed assets
Fixtures and
fittings
Computer
equipment
Total
Cost or valuation
At 1 April 2023
9.122
6,930
16,052
At 31 March 2024
9,122
6,930
16,052
Depreciation
At 1 April 2023
Charge for the year
9.091
31
4,992
14,083
915
At 31 March 2024
9.122
5,876
14,998
Net book value
At 31 March 2024
1,054
1,054
At 31 March 2023
31
1,938
1,969
12. Fixed asset investments
Investments
in
subsidiary
companies
Cost or valuation
At 1 April 2023
At 31 March 2024
Net book value
At 31 March 2024
At 31 March 2023

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
13. Debtors
2024
2023
Due within one year
Trade debtors
42.550
87,073
7.492
20.490
66,989
13,493
Amounts due from subsidiary undertakings
Prepayments and accrued income
137,115
100,972
14. Creditors: Amounts falling due within one year
2024
2023
Trade creditors
3.624
3,650
1.441
114,745
11,181
4, 829
1,309
152,666
Other taxation and social security
other creditors
Accruals and deferred income
123,460
169,985
2024
2023
Deferred income at 1 April 2023
Resources deferred during the year
Amounts released from previous periods
136,430
104,263
1136,430)
134,876
136.430
(134, 876)
104,263
136.430

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
15. Statement of funds
Statement of funds - current year
Balance at
31 March
2024
Balance at 1
April 2023
Income Expenditure
Unrestricted funds
General Fund
450,122
275.681
(281,140
444,663
Restricted funds
Educational Programme Fund
24,000
124,000
Total of funds
450,122
299,681
(305,140
444,663
16. Anatysis of net assets between funds
Anatysis of net assets between funds - current period
Unrestricted
funds
2024
Total
funds
2024
Tangible fixed assets
Intangible fixed assets
Fixed asset investments
1,054
44,956
1,054
44.956
Current assets
528,444
528.444
(123,460) 1123,460)
(6,332)
16,332)
Creditors due within one year
Capital grant
Total
444,663
444.663

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
16. Anatysis of net assets between funds (continued)
Anatysis of net assets between funds - prior period
Unrestricted
funds
2023
Total
funds
2023
Tangible fixed assets
Intangible fixed assets
Fixed asset investments
1,969
44, 956
1,969
44,956
Current assets
Creditors due within one year
Capital grant
579,513
(169, 985)
(6,332)
579,513
(169, 985)
(6, 332)
Total
450, 122
450, 122
17. Principal subsidiaries
The following was a subsidiary undertaking of the Society"
Name
Company
number
Pincipal place of business
Class of
shares
BBTS Enterprises Limited
4775642
England
Ordinary
Holding
100°/
The financial results of the subsidiary for the year were..
Name
Income
Expenditure
(Deficit) for
the year
BBTS Enterprises Limited
380,827
382,063
(1,236
Net assets
98,980